184 related articles for article (PubMed ID: 31684108)
41. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
Hombach-Klonisch S; Kalantari F; Medapati MR; Natarajan S; Krishnan SN; Kumar-Kanojia A; Thanasupawat T; Begum F; Xu FY; Hatch GM; Los M; Klonisch T
Mol Oncol; 2019 Feb; 13(2):153-170. PubMed ID: 30289618
[TBL] [Abstract][Full Text] [Related]
42. The FGFR inhibitor PD173074 binds to the C-terminus of oncofetal HMGA2 and modulates its DNA-binding and transcriptional activation functions.
Ahmed SM; Ragunathan P; Shin J; Peter S; Kleissle S; Neuenschwander M; Schäfer R; Kries JPV; Grüber G; Dröge P
FEBS Lett; 2023 Aug; 597(15):1977-1988. PubMed ID: 37259564
[TBL] [Abstract][Full Text] [Related]
43. Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer.
Nana AW; Chin YT; Lin CY; Ho Y; Bennett JA; Shih YJ; Chen YR; Changou CA; Pedersen JZ; Incerpi S; Liu LF; Whang-Peng J; Fu E; Li WS; Mousa SA; Lin HY; Davis PJ
Endocr Relat Cancer; 2018 Mar; 25(3):279-293. PubMed ID: 29255096
[TBL] [Abstract][Full Text] [Related]
44. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
Chen MH; Lin KJ; Yang WL; Kao YW; Chen TW; Chao SC; Chang PM; Liu CY; Tzeng CH; Chao Y; Chen MH; Yeh CN; Huang CY
Cancer; 2013 Jan; 119(2):293-303. PubMed ID: 22810956
[TBL] [Abstract][Full Text] [Related]
45. High Mobility Group A2 protects cancer cells against telomere dysfunction.
Natarajan S; Begum F; Gim J; Wark L; Henderson D; Davie JR; Hombach-Klonisch S; Klonisch T
Oncotarget; 2016 Mar; 7(11):12761-82. PubMed ID: 26799419
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of HMGA2 promotes tongue cancer metastasis through EMT pathway.
Zhao XP; Zhang H; Jiao JY; Tang DX; Wu YL; Pan CB
J Transl Med; 2016 Jan; 14():26. PubMed ID: 26818837
[TBL] [Abstract][Full Text] [Related]
47. Downregulation of HMGA2 inhibits cellular proliferation and invasion, improves cellular apoptosis in prostate cancer.
Cai J; Shen G; Liu S; Meng Q
Tumour Biol; 2016 Jan; 37(1):699-707. PubMed ID: 26242267
[TBL] [Abstract][Full Text] [Related]
48. Circulating cell-free high mobility group AT-hook 2 mRNA as a detection marker in the serum of colorectal cancer patients.
Sahengbieke S; Wang J; Li X; Wang Y; Lai M; Wu J
J Clin Lab Anal; 2018 May; 32(4):e22332. PubMed ID: 28948632
[TBL] [Abstract][Full Text] [Related]
49. HMGA2 facilitates epithelial-mesenchymal transition in renal cell carcinoma by regulating the TGF-β/Smad2 signaling pathway.
Kou B; Liu W; Tang X; Kou Q
Oncol Rep; 2018 Jan; 39(1):101-108. PubMed ID: 29138866
[TBL] [Abstract][Full Text] [Related]
50. RKIP suppresses the proliferation and metastasis of breast cancer cell lines through up-regulation of miR-185 targeting HMGA2.
Zou Q; Wu H; Fu F; Yi W; Pei L; Zhou M
Arch Biochem Biophys; 2016 Nov; 610():25-32. PubMed ID: 27651238
[TBL] [Abstract][Full Text] [Related]
51. An Integrated Bioinformatics Analysis Repurposes an Antihelminthic Drug Niclosamide for Treating HMGA2-Overexpressing Human Colorectal Cancer.
Leung SW; Chou CJ; Huang TC; Yang PM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31581665
[TBL] [Abstract][Full Text] [Related]
52. High mobility group A2 (HMGA2) promotes EMT via MAPK pathway in prostate cancer.
Hawsawi O; Henderson V; Burton LJ; Dougan J; Nagappan P; Odero-Marah V
Biochem Biophys Res Commun; 2018 Sep; 504(1):196-202. PubMed ID: 30177390
[TBL] [Abstract][Full Text] [Related]
53. MicroRNA-490-3p regulates cell proliferation and apoptosis by targeting HMGA2 in osteosarcoma.
Liu W; Xu G; Liu H; Li T
FEBS Lett; 2015 Oct; 589(20 Pt B):3148-53. PubMed ID: 26341146
[TBL] [Abstract][Full Text] [Related]
54. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
55. Downregulating HMGA2 attenuates epithelial-mesenchymal transition-induced invasion and migration in nasopharyngeal cancer cells.
Xia YY; Yin L; Jiang N; Guo WJ; Tian H; Jiang XS; Wu J; Chen M; Wu JZ; He X
Biochem Biophys Res Commun; 2015 Jul; 463(3):357-63. PubMed ID: 26025649
[TBL] [Abstract][Full Text] [Related]
56. Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells.
Xia C; Liang S; He Z; Zhu X; Chen R; Chen J
Eur J Pharmacol; 2018 Jul; 830():59-67. PubMed ID: 29704494
[TBL] [Abstract][Full Text] [Related]
57. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
[TBL] [Abstract][Full Text] [Related]
58. Novel heat shock protein 90 inhibitor NVP-AUY922 synergizes with the histone deacetylase inhibitor PXD101 in induction of death of anaplastic thyroid carcinoma cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Clin Endocrinol Metab; 2015 Feb; 100(2):E253-61. PubMed ID: 25389633
[TBL] [Abstract][Full Text] [Related]
59. Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays.
Su L; Bryan N; Battista S; Freitas J; Garabedian A; D'Alessio F; Romano M; Falanga F; Fusco A; Kos L; Chambers J; Fernandez-Lima F; Chapagain PP; Vasile S; Smith L; Leng F
Sci Rep; 2020 Nov; 10(1):18850. PubMed ID: 33139812
[TBL] [Abstract][Full Text] [Related]
60. Let-7a inhibits migration, invasion and epithelial-mesenchymal transition by targeting HMGA2 in nasopharyngeal carcinoma.
Wu A; Wu K; Li J; Mo Y; Lin Y; Wang Y; Shen X; Li S; Li L; Yang Z
J Transl Med; 2015 Mar; 13():105. PubMed ID: 25884389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
